4basebio (LON:4BB) Stock Price Up 3.5% – What’s Next?

4basebio PLC (LON:4BB)’s stock price traded up 3.5% on Friday . The stock traded as high as GBX 496.80 and last traded at GBX 496.80. 38 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 1,267 shares. The stock had previously closed at GBX 480.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada dropped their price target on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a research report on Monday, June 15th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of GBX 1,400.

4basebio Price Performance

The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The firm has a market cap of £76.93 million, a P/E ratio of -4.56 and a beta of 1.09. The business has a fifty day moving average of GBX 510.10 and a 200 day moving average of GBX 510.47.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.